. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Genet Med. 2021 Dec 3;24(3):564–575. doi: 10.1016/j.gim.2021.10.016

Table 3.

BRCA Prior Probability, Sex, and Early Participant Outcomes according to Test Result

Result	BRCA Prior Probability	Sex	Early Medical Follow-up and Intentions
138 (3.4%) Positive GT	21 (15.2%) Low Prior Probability of a PV	8 (38.1%) Male	59/69^a (85.5%) of participants who tested positive reported planning to increase the frequency of their cancer screening based on their test results.
	21 (15.2%) Low Prior Probability of a PV	13 (61.9%) Female
	31 (22.5%) Increased Prior Probability of a PV	11 (35.5%) Male
	31 (22.5%) Increased Prior Probability of a PV	20 (64.5%) Female
	86 (62.3%) Familial PV	57 (66.3%) Male
	86 (62.3%) Familial PV	29 (33.7%) Female
3,971 (96.6%) Negative GT	2,283 (57.5%) Low Prior Probability of a PV	482 (21.1%) Male
	2,283 (57.5%) Low Prior Probability of a PV	1,801 (78.9%) Female
	1,459 (36.7%) Increased Prior Probability of a PV	290 (19.9%) Male	23/630^a (3.7%) of participants with an increased prior probability of a PV who tested negative completed further recommended GT.
	1,459 (36.7%) Increased Prior Probability of a PV	1,169 (80.1%) Female
	229 (5.8%) Familial PV	92 (40.2%) Male
	229 (5.8%) Familial PV	137 (59.8%) Female

GT= Genetic Testing, PV = Pathogenic Variant.

Note that 50% of participants who tested positive have completed the 12-week follow-up survey, and 43.2% of Increased Prior Probability of a PV participants who tested negative have completed the follow-up survey.